In October 2017, the FDA approved a generic version, which is manufactured in India by Natco Pharma, and imported and sold by Dutch firm Mylan. In February 2018, Sandoz received FDA approval for their generic version. In parallel with the development and approval processes, the generic competitors have disputed Tevas newer patents, any of which if upheld, would prevent marketing of long-acting generics.While the patent on the chemical drug expired in 2015, Teva obtained new US patents covering pharmaceutical formulations for long-acting delivery. Litigation from industry competitors in 2016-2017 resulted in the new patents being judged invalid. In October 2018, the U.S. Court of Appeals for the Federal Circuit upheld the patent invalidation for obviousness. The case reflects the larger controversy over evergreening of generic drugs. References
Further reading
"Glatiramer acetate". Drug Information Portal. U.S. National Library of Medicine.
Inventors
Eptifibatide was discovered by a team led by Robert M. Scarborough  and David Phillips, at COR Therapeutics which was acquired by Millennium Pharmaceuticals in 2001. See also
Glycoprotein IIb/IIIa inhibitors

References
External links
"Eptifibatid/Intregrilin". Pharmazeutische Zeitung (in German). "From Bites and Stings to Medicines". The Royal Society of Chemistry. Archived from the original on 27 April 2006. (information on the biological origin of eptifibatide)
"Eptifibatide". Drug Information Portal. U.S. National Library of Medicine.